Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder

Alternative Medicine Review

Volumn 15, Issue 1, 2010, Pages 15-32

  Bradstreet, James Jeffrey ^a,b   Smith, Scott ^a   Baral, Matthew ^b   Rossignol, Daniel A ^a  

^a International Child Development Resource Center   (United States)

^b Southwest College Naturopathic Med   (United States)

Author keywords

ADD; ADHD; ASD; Attention deficit; Autism; Autistic; Biomarkers

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE; METAL;

ATTENTION DEFICIT DISORDER; AUTISM; COMORBIDITY; DISEASE ASSOCIATION; ENTERITIS; IMMUNOPATHOLOGY; METHYLATION; OXIDATIVE STRESS; REVIEW;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; INFLAMMATION; INTESTINAL DISEASES; MALE; METALS, HEAVY; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS;

EID: 77952501114     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA 2001;285:3093-3099. (Pubitemid 32578206)
2. Bertrand J, Mars A, Boyle C, et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001;108:1155-1161. (Pubitemid 33021192)
3. Baird G, Charman T, Baron-Cohen S, et al. A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry 2000;39:694-702. (Pubitemid 30351219)
4. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009;124:1395-1403.
5. Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry 2005;66:3-8. (Pubitemid 43133208)
6. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006;368:210-215. (Pubitemid 44037796)
7. Centers for Disease Control and Prevention (CDC). Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years - United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006;55:481-486.
8. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004;113:e472-e486.
9. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107:E43.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
11. Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006;63:1161-1164. (Pubitemid 44232325)
12. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141B:947-956. (Pubitemid 44905454)
13. Chauhan A, Chauhan V. Oxidat Oive stress in autism. Pathophysiology 2006;13:171-181.
14. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80:1611-1617. (Pubitemid 41103861)
15. Filipek PA, Juranek J, Nguyen MT, et al. Relative carnitine deficiency in autism. J Autism Dev Disord 2004;34:615-623.
16. Rossignol DA, Bradstreet JJ. Evidence of mitochondrial dysfunction in autism and implications for treatment. Am J Biochem Biotech 2008;4:208-217. (Pubitemid 351573654)
17. Adams JB, Baral M, Geis E, et al. The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels. J Toxicol 2009;2009:1-7.
18. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2009;280:101-108.
19. Bradstreet JJ, Geier DA, Kartzinel JJ, et al. A case-control study of mercury burden in children with autistic spectrum disorders. J Am Physicians Surg 2003;8:76-79.
20. Nataf R, Skorupka C, Amet L, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol 2006;214:99-108.
21. Eppright TD, Sanfacon JA, Horwitz EA. Attention deficit hyperactivity disorder, infantile autism, and elevated blood-lead: a possible relationship. Mo Med 1996;93:136-138.
22. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol 2004;70:6459-6465. (Pubitemid 39518551)
23. Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 2005;54:987-991.
24. Finegold SM, Molitoris D, Song Y, et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002;35:S6-S16.
25. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005;51:77-85. (Pubitemid 40522799)
26. Balzola F, Barbon V, Repici A, et al. Panenteric IBD-like disease in a patient with regressive autism shown for the first time by the wireless capsule enteroscopy: another piece in the jigsaw of this gut-brain syndrome? Am J Gastroenterol 2005;100:979-981.
27. Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol 2004;24:664-673. (Pubitemid 40933118)
28. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57:67-81. (Pubitemid 40053317)
29. Ohnishi T, Matsuda H, Hashimoto T, et al. Abnormal regional cerebral blood flow in childhood autism. Brain 2000;123:1838-1844.
30. Ito H, Mori K, Hashimoto T, et al. Findings of brain 99mTc-ECD SPECT in high-functioning autism - 3-dimensional stereotactic ROI template analysis of brain SPECT. J Med Invest 2005;52:49-56. (Pubitemid 40502568)
31. Ross BM, McKenzie I, Glen I, Bennett CP. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci 2003;6:277-281. (Pubitemid 37361909)
32. Ross MA. Could oxidative stress be a factor in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 2000;63:61-63.
33. Chovanova Z, Muchova J, Sivonova M, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radic Res 2006;40:1003-1010. (Pubitemid 44480565)
34. Tuthill RW. Hair lead levels related to children's classroom attention-deficit behavior. Arch Environ Health 1996;51:214-220.
35. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006;114:1904-1909. (Pubitemid 44873693)
36. Dvorakova M, Sivonova M, Trebaticka J, et al. The effect of polyphenolic extract from pine bark, Pycnogenol on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). Redox Rep 2006;11:163-172.
37. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006;18:155-172. (Pubitemid 43791677)
38. Amen DG, Carmichael BD. High-resolution brain SPECT imaging in ADHD. Ann Clin Psychiatry 1997;9:81-86. (Pubitemid 27364030)
39. O'Hara NH, Szakacs GM. The recovery of a child with autism spectrum disorder through biomedical interventions. Altern Ther Health Med 2008;14:42-44.
40. Granpeesheh D, Tarbox J, Dixon DR, et al. Retrospective analysis of clinical records in 38 cases of recovery from autism. Ann Clin Psychiatry 2009;21:195-204.
41. Eikeseth S, Smith T, Jahr E, Eldevik S. Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: a comparison controlled study. Behav Modif 2007;31:264-278.
42. Cohen H, Amerine-Dickens M, Smith T. Early intensive behavioral treatment: replication of the UCLA model in a community setting. J Dev Behav Pediatr 2006;27:S145-S155. (Pubitemid 44620296)
43. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard 1993;97:359-372; discussion 373-391.
44. Israngkun PP, Newman HA, Patel ST, et al. Potential biochemical markers for infantile autism. Neurochem Pathol 1986;5:51-70.
45. Chakravarty A. Regulatory aspects in using surrogate markers in clinical trials. In: Burzykowski T, Molenberghs G, Buyse M, eds. Statistics for Biology and Health. The Evaluation of Surrogate Endpoints. New York, NY: Springer Science+Business Media, Inc.; 2005:13-51.
46. Bruchfeld A, Carrero JJ, Qureshi AR, et al. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med 2009;15:70-75.
47. Sajdel-Sulkowska EM, Lipinski B, Windom H, et al. Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. Am J Biochem Biotech 2008;4:73-84. (Pubitemid 351573641)
48. Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 2007;82:297-325.
49. Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 2003;160:1691-1693.
50. Warren RP, Yonk LJ, Burger RA, et al. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest 1990;19:245-251.
51. Denney DR, Frei BW, Gaffney GR. Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord 1996;26:87-97. (Pubitemid 126738401)
52. Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 1977;7:49-55.
53. Yonk LJ, Warren RP, Burger RA, et al. CD4+ helper T cell depression in autism. Immunol Lett 1990;25:341-345.
54. Croonenberghs J, Wauters A, Devreese K, et al. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 2002;32:1457-1463. (Pubitemid 35385656)
55. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One 2008;3:e3815.
56. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006;21:170-172. (Pubitemid 43772660)
57. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res 1997;10:143-148. (Pubitemid 127524358)
58. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes Res 1997;10:149-156.
59. Mousain-Bosc M, Roche M, Polge A, et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res 2006;19:53-62.
60. Bekaroglu M, Asian Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996;37:225-227. (Pubitemid 26093391)
61. Arnold LE, Bozzolo H, Hollway J, et al. Serum zinc correlates with parent- and teacher- rated inattention in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:628-636. (Pubitemid 41434367)
62. Yorbik O, Akay C, Sayal A, et al. Zinc status in autistic children. J Trace Elem Exp Med 2004;17:101-107.
63. Adams JB, Holloway CE, George F, Quig D. Analyses of toxic metals and essential minerals in the hair of Arizona children with autism and associated conditions, and their mothers. Biol Trace Elem Res 2006;110:193-209. (Pubitemid 44127933)
64. Jory J, McGinnis WR. Red-cell trace minerals in children with autism. Am J Biochem Biotech 2008;4:101-104. (Pubitemid 351573644)
65. Oshiro M, Mimura S, Hayakawa M, Watanabe K. Plasma and erythrocyte levels of trace elements and related antioxidant enzyme activities in low-birthweight infants during the early postnatal period. Acta Paediatr 2001;90:1283-1287. (Pubitemid 33144992)
66. Starobrat-Hermelin B. The effect of deficiency of selected bioelements on hyperactivity in children with certain specified mental disorders. Ann Acad Med Stetin 1998;44:297-314. [Article in Polish]
67. Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2004;158:1113-1115. (Pubitemid 39579170)
68. Konofal E, Cortese S, Marchand M, et al. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med 2007;8:711-715.
69. Latif A, Heinz P, Cook R. Iron deficiency in autism and Asperger syndrome. Autism 2002;6:103-114.
70. Dosman CF, Drmic IE, Brian JA, et al. Ferritin as an indicator of suspected iron deficiency in children with autism spectrum disorder: prevalence of low serum ferritin concentration. Dev Med Child Neurol 2006;48:1008-1009.
71. Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008;38:20-26. (Pubitemid 350181289)
72. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007;36:152-158.
73. Gillberg IC, Gillberg C, Kopp S. Hypothyroidism and autism spectrum disorders. J Child Psychol Psychiatry 1992;33:531-542.
74. Weiss RE, Stein MA, Trommer B, Refetoff S. Attention-deficit hyperactivity disorder and thyroid function. J Pediatr 1993;123:539-545. (Pubitemid 23287522)
75. Tierney E, Bukelis I, Thompson RE, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006;141B:666-668. (Pubitemid 44434669)
76. Zhang J, Muldoon MF, McKeown RE, Cuffe SP. Association of serum cholesterol and history of school suspension among school-age children and adolescents in the United States. Am J Epidemiol 2005;161:691-699. (Pubitemid 40411097)
77. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006;66:182-188.
78. de Bruin EI, Verheij F, Wiegman T, Ferdinand RF. Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders. Dev Med Child Neurol 2006;48:962-965. (Pubitemid 44768797)
79. Sanfeliu C, Sebastia J, Ki SU. Methylmercury neurotoxicity in cultures of human neurons, astrocytes, neuroblastoma cells. Neurotoxicology 2001;22:317-327. (Pubitemid 32612375)
80. Deth R, Muratore C, Benzecry J, et al. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29:190-201.
81. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci 2004;75:2539-2549. (Pubitemid 39195260)
82. Cagnon L, Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res Rev 2007;56:183-197. (Pubitemid 350100868)
83. Chinnery PF. Mitochondrial disorders overview, http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book=gene&part=mt-overview [Accessed January 19, 2010]
84. Chinnery PF, Turnbull DM. Mitochondrial medicine. QJM 1997;90:657-667.
85. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005;47:185-189. (Pubitemid 40277824)
86. Correia C, Coutinho AM, Diogo L, et al. Brief report: High frequency of biochemical markers for mitochondrial dysfunction in autism: no association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene. J Autism Dev Disord 2006;36:1137-1140.
87. Svoboda P, Maekawa M, Kawai K, et al. Urinary 8-hydroxyguanine may be a better marker of oxidative stress than 8-hydroxydeoxyguanosine in relation to the life spans of various species. Antioxid Redox Signal 2006;8:985-992. (Pubitemid 44036515)
88. Ming X, Stein TP, Brimacombe M, et al. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Adds 2005;73:379-384. (Pubitemid 41375634)
89. Eyles D, Brown J, Mackay-Sim A, et al. Vitamin D3 and brain development. Neuroscience 2003;118:641-653.
90. Cannell JJ. Autism and vitamin D. Med Hypotheses 2008;70:750-759.
91. Bejerot S, Humble M. Increased occurrence of autism among Somali children - does vitamin D deficiency play a role? Tidsskr Nor Laegeforen 2008;128:1986-1987. [Article in Swedish]
92. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-105. (Pubitemid 36733998)
93. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29:346-351.
94. Lin AM, Chen KB, Chao PL. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci 2005;1053:319-329. (Pubitemid 43031112)
95. James SJ, Slikker W 3rd, Melnyk S, et al. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005;26:1-8.
96. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalarnin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89:425-430.
97. Waring RH, Ngong JM, Klovrza L, et al. Biochemical parameters in autistic children. Dev Brain Dysfunct 1997;10:40-43.
98. O'Reilly BA, Waring RH. Enzyme and sulphur oxidation deficiencies in autistic children with known food/chemical intolerances. J Orthomolecular Med 1993;8:198-200.
99. Alberti A, Pirrone P, Elia M, et al. Sulphation deficit in "low-functioning" autistic children: a pilot study. Biol Psychiatry 1999;46:420-424.
100. Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr 2002;14:583-587.
101. McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology 1996;111:43-65.
102. Connolly AM, Chez M, Streif EM, et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffher syndrome, and epilepsy. Biol Psychiatry 2006;59:354-363.
103. Connolly AM, Chez MG, Pestronk A, et al. Serum autoantibodies to brain in Landau-Kleffher variant, autism, and other neurologic disorders. J Pediatr 1999;134:607-613. (Pubitemid 30180601)
104. Messahel S, Pheasant AE, Pall H, et al. Urinary levels of neopterin and biopterin in autism. Neurosci Lett 1998;241:17-20. (Pubitemid 28079023)
105. Messahel S, Pheasant AE, Pall H, Kerr AM. Abnormalities in urinary pterin levels in Rett syndrome. Eur J Paediatr Neurol 2000;4:211-217.
106. Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000;30:475-479.
107. Heuer L, Ashwood P, Schauer J, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 2008;1:275-283.
108. Oleske J. Another view of autism. The University of Medicine & Dentistry of New Jersey Research 2004;Winter:22-23.
109. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996;26:439-452. (Pubitemid 26269874)
110. Stern L, Francoeur MJ, Primeau MN, et al. Immune function in autistic children. Ann Allergy Asthma Immunol 2005;95:558-565.
111. Warren RP, Odell JD, Warren WL, et al. Brief report: immunoglobulin A deficiency in a subset of autistic subjects. J Autism Dev Disord 1997;27:187-192.
112. Plioplys AV. Intravenous immunoglobulin treatment in autism. J Autism Dev Disord 2000;30:73-74.
113. Winterkamp S, Weidenhiller M, Otte P, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002;97:3071-3077. (Pubitemid 35424578)
114. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007;36:361-365. (Pubitemid 46873913)
115. Giedd JN, Rapoport JL, Leonard HL, et al. Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. J Am Acad Child Adolesc Psychiatry 1996;35:913-915.
116. Snider LA, Lougee L, Slattery M, et al. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry 2005;57:788-792. (Pubitemid 40487923)
117. Swedo SE, Garvey M, Snider L, et al. The PANDAS subgroup: recognition and treatment. CNS Spectr 2001;6:419-422,425-426.
118. Balzola F, Daniela C, Repici A, et al. Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology 2005;128:A303.
119. Torrente F, Ashwood P, Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002;7:375-382,334.
120. Horvath K, Papadimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999;135:559-563. (Pubitemid 30180444)
121. Valicenti-McDermott M, McVicar K, Rapin I, et al. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr 2006;27:S128-S136.
122. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 2002;4:251-258.
123. Jyonouchi H, Geng L, Ruby A, et al. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr 2005;146:605-610. (Pubitemid 40616244)
124. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable noninvasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-553.
125. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008;14:1229-1235.
126. Peterson CG, Hansson T, Skott A, et al. Detection of local mast-cell activity in patients with food hypersensitivity. J Investig Allergol Clin Immunol 2007;17:314-320. (Pubitemid 350012546)
127. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008;14:359-366. (Pubitemid 351441325)
128. Fernell E, Fagerberg UL, Hellstrom PM. No evidence for a dear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr 2007;96:1076-1079. (Pubitemid 46934435)
129. D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 1996;85:1076-1079. (Pubitemid 26302768)
130. Robertson MA, Sigalet DL, Hoist JJ, et al. Intestinal permeability and glucagon-like peptide-2 in children with autism: a controlled pilot study. J Autism Dev Disord 2008;38:1066-1071.
131. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-641.
132. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15:429-435.
133. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr 2007;137:819S-824S.
134. Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with celiac disease. Pediatrics 2004;113:1672-1676. (Pubitemid 38697975)
135. Barcia G, Posar A, Santucci M, Parmeggiani A. Autism and coeliac disease. J Autism Dev Disord 2008;38:407-408.
136. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med 1995;37:137-141.
137. Jenkins M, Vickers A. Unreliability of IgE/IgG4 antibody testing as a diagnostic tool in food intolerance. Clin Exp Allergy 1998;28:1526-1529. (Pubitemid 29003328)
138. Oehling A, Fernandez M, Cordoba H, Sanz ML. Skin manifestations and immunological parameters in childhood food allergy. J lnvestig Allergol Clin Immunol 1997;7:155-159. (Pubitemid 27344628)
139. Buie TM. Gastroesophageal reflux in children with autism: how do children present and can one test these children? J Pediatr Gastroenterol Nutr 2005;41:505.
140. Stern AH. A revised probabilistic estimate of the maternal methyl mercury intake dose corresponding to a measured cord blood mercury concentration. Environ Health Perspect 2005;113:155-163.
141. David OJ. Association between lower level lead concentrations and hyperactivity in children. Environ Health Perspect 1974;7:17-25.
142. David OJ, Hoffman SP, Clark J, et al. The relationship of hyperactivity to moderately elevated lead levels. Arch Environ Health 1983;38:341-346. (Pubitemid 14186862)
143. Nigg JT, Knottnerus GM, Martel MM, et al. Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol Psychiatry 2008;63:325-331.
144. Lidsky TI, Schneider JS. Autism and autistic symptoms associated with childhood lead poisoning. J Appl Res 2005;5:80-87. (Pubitemid 40503481)
145. Cheuk DK, Wong V. Attention-deficit hyperactivity disorder and blood mercury level: a case-control study in Chinese children. Neuropediatrics 2006;37:234-240. (Pubitemid 46092371)
146. Soden SE, Lowry JA, Garrison CB, Wasserman GS. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila) 2007;45:476-481.
147. Chrysochoou C, Rutishauser C, Rauber-Luthy C, et al. An 11-month-old boy with psychomotor regression and auto-aggressive behaviour. Eur J Pediatr 2003;162:559-561. (Pubitemid 36904299)
148. Palmer RF, Blanchard S, Wood R. Proximity to point sources of environmental mercury release as a predictor of autism prevalence. Health Place 2009;15:18-24.
149. Palmer RF, Blanchard S, Stein Z, et al. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place 2006;12:203-209. (Pubitemid 41774048)
150. Windham GC, Zhang L, Gunier R, et al. Autism spectrum disorders in relation to distribution of hazardous air pollutants in the San Francisco bay area. Environ Health Perspect 2006;114:1438-1444. (Pubitemid 44314771)
151. Rury J. Links between environmental mercury, special education, and autism in Louisiana. Masters Thesis. Louisiana State University, 2006.
152. Filipek PA, Accardo PJ, Baranek GT, et al. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 1999;29:439-484.
153. Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003;348:1517-1526.
154. Clarkson TW. The three modern faces of mercury. Environ Health Perspect 2002;110:11-23.
155. Bergdahl IA, Vahter M, Counter SA, et al. Lead in plasma and whole blood from lead-exposed children. Environ Res 1999;80:25-33.
156. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A 2007;70:1723-1730. (Pubitemid 47450885)
157. Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res 2006;10:57-64.
158. Austin DW, Shandley K. An investigation of porphyrinuria in Australian children with autism. J Toxicol Environ Health A 2008;71:1349-1351.
159. Heyer NJ, Bittner AC Jr, Echeverria D, Woods JS. A cascade analysis of the interaction of mercury and coproporphyrinogen oxidase (CPOX) polymorphism on the heme biosynthetic pathway and porphyrin production. Toxicol Lett 2006;161:159-166. (Pubitemid 41790289)
160. Woods JS, Echeverria D, Heyer NJ, et al. The association between genetic polymorphisms of coproporphyrinogen oxidase and an atypical porphyrinogenic response to mercury exposure in humans. Toxicol Appl Pharmacol 2005;206:113-120. (Pubitemid 40828234)
161. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol 2009;9:17.
162. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A - medical results. BMC Clin Pharmacol 2009;9:16.
163. Blades M. Autism: an interesting dietary case history. Nutr Food Sci 2000;30:137-140.
164. Brudnak MA, Rimland B, Kerry RE, et al. Enzyme-based therapy for autism spectrum disorders - is it worth another look? Med Hypotheses 2002;58:422-428.
165. Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:765-774. (Pubitemid 23280951)
166. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002;17:833-837.
167. Ellaway CJ, Peat J, Williams K, et al. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev 2001;23:S85-S89.
168. Trebaticka J, Kopasova S, Hradecna Z, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry 2006;15:329-335.
169. Torrioli MG, Vernacotola S, Peruzzi L, et al. A double-blind, parallel, multi-center comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 2008;146:803-812.
170. Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:181-190. (Pubitemid 37548510)
171. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral
172. Harding KL, Judah RD, Gant C. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. Altern Med Rev 2003;8:319-330. (Pubitemid 37099890)
173. Bradstreet JJ, Smith S, Granpeesheh D, et al. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses 2007;68:979-987. (Pubitemid 46290607)
174. Boris M, Kaiser CC, Goldblatt A, et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation 2007;4:3.
175. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009;21:213-236.
176. Boris M, Goldblatt A, Edelson SM. Improvement in children with autism treated with intravenous gamma globulin. J Nutr Environ Med 2005;15:169-176. (Pubitemid 44049798)